- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.01. | RFK Jr. thrusts domestic manufacturing agenda on Day 2 of confirmation hearings | ||
| 30.01. | MHRA launches refreshed ILAP to speed up NHS drug access | ||
| 30.01. | Takeda announces appointment of Julie Kim as CEO | ||
| 30.01. | WHO's Neglected Tropical Disease Day at unfamiliar odds with US stance | ||
| 30.01. | Leveragen and Moonlight Bio unite for T-cell therapy development | ||
| 30.01. | Acellera and Psivant partner for AI-driven drug discovery | ||
| 29.01. | Lyndra Therapeutics appoints Adam Sayer new CEO and president | ||
| 29.01. | FDA expands Enhertu approval to include HER2-ultralow breast cancer patients | ||
| 29.01. | Lantheus acquires radiopharma CDMO Evergreen for up to $1bn | ||
| 29.01. | Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD | ||
| 29.01. | Sonnet BioTherapeutics secures EU patent for FHAB technology | ||
| 29.01. | Will European PFAS ban disrupt pharma supply chains? | ||
| 29.01. | FDA RMAT designation for Beacon's retinitis pigmentosa treatment | ||
| 28.01. | ITM's radiotherapeutic beats out standard-of-care in Phase III trial | ||
| 28.01. | Allakos cuts 75% of workforce after chronic hives trial failure | ||
| 28.01. | GLP-1RA developer Metsera targets $289m IPO | ||
| 28.01. | Can-Fite BioPharma secures US patent for Namodenoson | ||
| 28.01. | Sage rejects Biogen's $469m takeover bid | ||
| 28.01. | OCT West Coast 2025: Efficient trials will help at all levels | ||
| 28.01. | AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal | ||
| 28.01. | AI-driven virtual CGM data boosts understanding of T1D risks | ||
| 28.01. | GSK and University of Oxford partner for cancer vaccine research | ||
| 27.01. | Pfizer settles Biohaven kickback claims case for $59.7m | ||
| 27.01. | MSD wins FDA priority review for Welireg in rare endocrine cancer | ||
| 27.01. | The AI advantage in discovering new medicines |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
